Literature DB >> 3696497

Age-related recurrence of basal forebrain lesion-induced cholinergic deficits.

G F Hohmann1, G L Wenk, P Lowenstein, M E Brown, J T Coyle.   

Abstract

Lesions of basal forebrain cholinergic nuclei projecting in neocortex have recently been employed as an animal model for the cholinergic deficits in Alzheimer's disease. However, unlike Alzheimer's patients, whose deterioration appears to be progressive and irreversible, basalis lesioned rats usually recover both behaviorally and neurochemically within several months after the lesion. We now demonstrate that this recovery may be a function of the age of the rat and that cholinergic deficits re-occur in the aged rat. Choline acetyltransferase (ChAT) activity and [3H]hemicholinium-3 ([3H]HCh-3) binding are reduced in cortex ipsilateral to ibotenic acid lesions in the 12-month postlesion rat following an initial recovery to normal levels by about 3 months postlesion. The recurrence of decrease of cholinergic markers is not a consequence of a non-specific age-related decline since the activity of glutamic acid decarboxylase remains constant between 3 and 12 months postlesion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3696497     DOI: 10.1016/0304-3940(87)90265-5

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  3 in total

1.  Effects of lesion of the cholinergic basal forebrain nuclei on the activity of glutamatergic and GABAergic systems in the rat frontal cortex and hippocampus.

Authors:  G Reine; D Samuel; A Nieoullon; L Kerkerian-Le Goff
Journal:  J Neural Transm Gen Sect       Date:  1992

2.  Coeloglossum viride var. bracteatum extract protects against amyloid toxicity in rat prefrontal cortex neurons.

Authors:  Xiao-Yan Qin; Jia Cui; Yan Zhang
Journal:  Int J Clin Exp Med       Date:  2010-03-20

3.  Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice.

Authors:  J E Sweeney; E S Bachman; J T Coyle
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.